Adamyan 2015a.

Study characteristics
Methods	Study design: RCT Unit of randomisation: No information Total duration of study: 36 months Run‐in period: No information Intervention time: No information Follow‐up: No information Setting: Institute of Cardiology, Yerevan, Armenia
Participants	Type of heart failure: CHF N = 104 participants (ivabradine and BB: 51; SC: 53) Mean age: 63.2 years (no SD reported) Gender: No information Severity of condition: No information Inclusion criteria: CHF Preserved LV ejection fraction NYHA class III Exclusion criteria: No information Withdrawals: No information
Interventions	Intervention: Ivabradine max. 7.5 mg twice a day Comparison: SC Concomitant medications: beta‐secretase inhibitors BB Diuretics Excluded medications: No information
Outcomes	Outcomes and time points measured in the study: [Day 0, Month 12, 24, and 36] Deceleration time of transmitral E waves Deceleration time of transtricuspidal E waves E/A ratio of transmitral flow RV fractional area change Tricuspidal annulus plane systolic excursion Pulmonary artery ejection time RA and LA fractional contribution Functional index Relation of pulmonary vein Systolic and diastolic fraction Systolic contribution Difference between duration of reversal atrial flow Late transmitral filling NT‐pro‐BNP level C‐reactive protein level Conclusion: "1. Decrease of NT‐pro‐BNP ≥ 50 %, reversal atrial flow to late transmitral filling ≥ 80%, C‐reactive protein level ≥ 40%, HR ≥ 25% and increase of Deceleration time of transmitral E waves (ECG) ≥ 80%, RA and LA functional index, pulmonary vein systolic contribution ≥ 50%, RA and LA fractional contribution, RV fractional area change, Deceleration time of transtricuspidal E waves and pulmonary artery ejection time at ≥ 25% identified pts with cardiac risk reduction." "2. Ivabradine use associated with lower mortality and morbidity due to significant improvement of left ventricular, right ventricular, left atrial and right atrial functional parameters, neurohormonal and inflammation status and HR reduction."
Notes	Funding for trial: No information Notable conflicts of interest of authors: No information Contact to authors/unpublished data: We contacted KG Adamyan and S Grigoryan via email on 22 November 2018 to ask for funding, country, number of centres, and missing data. The email to KG Adamyan failed, but S Grigoryan answered that she had forwarded the email to the correct email address. Nevertheless, we did not receive an answer.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Insufficient information to base judgement
Allocation concealment (selection bias)	Unclear risk	Insufficient information to base judgement
Blinding of participants and personnel (performance bias) All outcomes	High risk	No blinding possible due to comparison with standard care.
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Insufficient information to base judgement
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Insufficient information to base judgement
Selective reporting (reporting bias)	Unclear risk	Insufficient information to base judgement
Other bias	Unclear risk	Insufficient information to base judgement